Sandoz CEO warns of Trump’s generic drug tariff threat
American patients would ultimately bear the cost of President Donald Trump's threatened tariffs on generic drugs, the CEO of Swiss...
HEALTH & FITNESS
AstraZeneca COPD drug tozorakimab shows positive late-stage trial results
AstraZeneca on Tuesday released full results from two successful late-stage trials on its experimental drug for chronic obstructive pulmonary disease,...
Novartis stock plummets 10% after third trial disappointment in a week
FILE PHOTO: The logo of Swiss drugmaker Novartis is seen at the company's new cell and gene therapy factory in...
Novartis trial failure raises stakes for Amgen and Eli Lilly in Lp(a) drug race
Blood sample for a lipoprotein(a) test.Md Babul Hosen | Istock | Getty ImagesNovartis' failure in a closely watched cardiovascular trial...
Here are 3 defensive stock market moves I’m making as oil and rates surge
Key PointsCNBC's Jim Cramer is taking a more defensive approach as rising oil prices, higher interest rates, and geopolitical tensions...
This medical device stock looks like a gift for patient investors
Insulet is a high-quality compounder where a temporary execution issue is masking strong underlying fundamentals. Type 2 diabetes represents a...
We’re adding 2 stocks to our Bullpen watchlist because they meet this criteria
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time...
August was the month of the comeback kids. Cramer reviews what drove the biggest winners
CNBC's Jim Cramer said Monday that August was a comeback month for stocks that had been battered by some of...
BioCryst is profitable. Now it wants to buy more rare disease drugs
CNBC Cures is proudly underwritten by Alexion, AstraZeneca Rare Disease, whose support enables our journalism to elevate stories that advance...
How Taylor Farms became integral to America’s food supply system
The cyclospora outbreak that has sickened thousands of people across the U.S. has brought fresh scrutiny of the integral role...
FDA approves Gilead HIV pill Bixlenvo designed to simplify treatment
Gilead Bixlenvo drugCourtesy: GileadThe Food and Drug Administration approved a once-daily HIV pill from Gilead that could help simplify care...
HHS plans new FDA leadership roles for technology, drugs
The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human...
BioMarin to acquire Alesta Therapeutics for $275 million
Piotr Swat | Lightrocket | Getty ImagesCNBC Cures is proudly underwritten by Alexion, AstraZeneca Rare Disease, whose support enables our...
Moderna, Merck cancer vaccine shows initial late-stage melanoma data
An experimental personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial, the companies...
Hims & Hers CEO Andrew Dudum talks FTC lawsuit, GLP-1s, AI
Hims & Hers CEO Andrew Dudum defended the telehealth company amid a Federal Trade Commission lawsuit over its data sharing...
The startup using AI to help build custom treatments for rare diseases
Jacalyn Lee, founder of The DAND Alliance, and her youngest daughter Isla.Jacalyn LeeCNBC Cures is proudly underwritten by Alexion, AstraZeneca...
Court rules companies can’t import Gilead medications from overseas
Nikos Pekiaridis | Nurphoto | Getty ImagesA court ruling this week in favor of Gilead Sciences could significantly impact a...
Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair'
Novo Nordisk CEO defended the company's decision to sue rival Eli Lilly over its weight-loss drug advertising. Source link
Trump ends Medicaid, CHIP funding for gender-affirming care for children
Supporters of transgender youth demonstrate outside Children's Hospital Los Angeles (CHLA) on February 6, 2025 in the wake of US...
We’re lifting our price target on Cardinal Health after issuing rosy profit guidance
Cardinal Health on Tuesday showed why the healthcare distributor belongs in our portfolio, delivering robust full-year earnings guidance that trumped...
